Pacira Pharmaceuticals (PCRX) is Set to Break Out in 2020 - RBC Capital
Tweet Send to a Friend
RBC Capital analyst, Randall Stanicky, reiterated an Outperform rating and $65.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX) after hosting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
